Ligand Express

Our Science

Traditional design of small molecule therapies has focused on specific, disease-associated protein targets which has led to the development of many breakthrough medicines. However, once a drug enters the body it interacts with dozens, if not hundreds, of proteins before it is excreted. These off-target interactions can represent threats to the safety of a drug, or potential repurposing opportunities. Cyclica's drug first, proteome-wide approach focuses on a drug's polypharmacology — all the proteins it interacts with — to provide insights into repurposing efforts, target identification, lead prioritization, and adverse effect elucidation. 


Ligand Express™

Cyclica Inc. has developed, validated, patented and commercialized Ligand Express™, a cloud-based platform that screens small-molecule drugs against repositories of structurally-characterized proteins or ‘proteomes’ to determine polypharmacological profiles. Accordingly, Ligand Express™ identifies significant protein targets using an innovative structure-based and drug-centric technology, leverages artificial intelligence to determine the drug’s effect on these targets, and visualizes the predicted drug-protein interactome using bioinformatics and systems biology. The platform provides a unique panoramic view of a small-molecule, by identifying on- and off-target interactions that may be expected, as well as those that are unanticipated. By understanding how a small-molecule drug will interact with all proteins in the body, Ligand Express™ augments scientific investigation by elucidating mechanism of action, prioritizing lead candidates, understanding side effects, as well as determining new uses for existing drugs. You can access our platform at